EP4117669A1 - Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2 - Google Patents

Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2

Info

Publication number
EP4117669A1
EP4117669A1 EP21717141.2A EP21717141A EP4117669A1 EP 4117669 A1 EP4117669 A1 EP 4117669A1 EP 21717141 A EP21717141 A EP 21717141A EP 4117669 A1 EP4117669 A1 EP 4117669A1
Authority
EP
European Patent Office
Prior art keywords
diltiazem
sars
berberine
cov
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21717141.2A
Other languages
German (de)
English (en)
French (fr)
Inventor
Manuel Rosa-Calatrava
Olivier Terrier
Mario Andres PIZZORNO
Aurélien TRAVERSIER
Blandine PADEY
Thomas Julien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signia Therapeutics
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Normale Superieure de Lyon
Original Assignee
Signia Therapeutics
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Normale Superieure de Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signia Therapeutics, Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 UCBL, Institut National de la Sante et de la Recherche Medicale INSERM, Ecole Normale Superieure de Lyon filed Critical Signia Therapeutics
Publication of EP4117669A1 publication Critical patent/EP4117669A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to a novel therapeutic use of known therapeutic compounds, alone or in combination with other active agents, to treat viral infection with the severe acute respiratory syndrome coronavirus SARS-CoV-2, otherwise referred to as coronavirus disease 2019. (COVID-19).
  • ARIs Human acute respiratory infections
  • ARIs represent one of the main causes of consultations, hospitalizations and deaths worldwide, being the leading cause of death in young children with nearly 2 million deaths per year.
  • viruses occupy a prominent place. They are indeed found in the majority of cases of childhood pneumonia and are a predisposing factor for bacterial pneumonia in adults.
  • Coronaviruses are enveloped viruses, possessing a capsid exhibiting helical symmetry. They have a single-stranded, positive-sense RNA genome and are capable of infecting cells of birds and mammals.
  • Coronavirus infections can cause respiratory pathologies associated with symptoms similar to the common cold (caused in particular by the hCoV and OC43 viruses), bronchiolitis (caused by the NL63 virus) or even more serious illnesses such as severe acute respiratory syndrome. caused by SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) which generated an epidemic in 2003, and Middle East respiratory syndrome due to MERS-CoV, which generated an epidemic in 2012.
  • SARS-CoV severe Acute Respiratory Syndrome Coronavirus
  • the Severe Acute Respiratory Syndrome Coronavirus 2 is the coronavirus that caused the 2019-2020 coronavirus outbreak, generating the form of pneumonia referred to as 2019 coronavirus disease (COVID-19).
  • This epidemic was declared a "public health emergency of international concern" by the World Health Organization (WHO) on January 30, 2020.
  • WHO World Health Organization
  • the first patient was reported for the first time in the city of Wuhan (Hubei province, People's Republic of China).
  • 111,321 cases have been confirmed worldwide, including 3,892 deaths in 109 countries.
  • the SARS-CoV-2 virus belongs to the species Severe acute respiratory syndrome-related coronavirus, in the genus Betacoronavirus and the family Coronaviridae (Gorbalenya et al., 2020).
  • the morphology of the virions is typical of that of the coronaviruses, with in particular the halo of protein protuberances (“Spike”) which gave them their name of “crown virus”.
  • Symptoms of SARS-CoV-2 infection roughly resemble those of seasonal flu: they include fever, fatigue, dry cough, shortness of breath, difficulty breathing, pneumonia, kidney failure , and can go as far as the death of the patient in severe cases (Hui et al., 2020).
  • the incubation period of SARS-CoV-2 is estimated to be between 2 and 14 days, but the incubation period would be longer in some cases, up to 24 days.
  • Antiviral compounds known for their therapeutic activities on other types of virus, are currently being tested in phase 2 and 3 clinical trials. They are in particular compounds that are inhibitors of cellular or viral proteases, and of nucleoside analogues. These various therapeutic compounds are in particular Remdesivir, Galidesivir, Lopinavir, Camostat mesilate and Chloroquine. Remdesivir
  • Remdesivir is a broad spectrum antiviral compound, acting as a nucleoside analogue, more specifically an adenosine analogue. Available as a lyophilisate, this compound is administered intravenously. It is metabolized to its active nucleotide analog form (GS-441524): its presence misleads viral polymerase and causes reduced viral RNA synthesis.
  • Remdesivir was developed by the company Gilead Science for the treatment of infections with the Ebola and Marburg viruses. It also exhibits antiviral activity against other single-stranded RNA viruses such as Nipah, Hendra, Lassa viruses, respiratory syncytial virus (RSV) and SARS and MERS coronaviruses, in preclinical models (Lo et al., 2017) .
  • RNA viruses such as Nipah, Hendra, Lassa viruses, respiratory syncytial virus (RSV) and SARS and MERS coronaviruses
  • Remdesivir has been studied so far in healthy volunteers and in patients infected with the Ebola virus. Treatments prescribed for a few patients with SARS-CoV-2 infection have not provided information on the safety and / or effectiveness in the treatment of SARS-CoV-2 infection. In addition, based on limited clinical experience, the toxicity and therefore safety profile of this compound is not characterized at this stage. Remdesivir has not yet received marketing authorization.
  • Galidesivir (BCX4430) is a nucleoside analogue, in particular adenosine, developed by the company BioCryst Pharmaceuticals.
  • This antiviral compound was initially developed for use against the hepatitis C virus and subsequently against filoviruses such as Ebola virus and Marburg virus.
  • Galidesivir protects against Ebola virus disease and Marburg virus disease in rodents and monkeys when administered up to 48 hours after exposure to the virus. Its development for use in humans has been accelerated in order to address the lack of available treatments to combat the Ebola virus disease epidemic in West Africa.
  • RNA viruses such as bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.
  • Molnupiravir (also referred to as EIDD-2801 and MK-4482) is an antiviral compound which has the advantage of being in a form suitable for oral administration.
  • This compound is a prodrug which is metabolized after ingestion into N4-hydroxycytidine, a nucleoside derivative which inhibits RNA viruses by introducing RNA replication errors by the viral RNA-dependent RNA polymerase.
  • This compound has been tested for its anti-influenza activity. It also has some activity against coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-2, responsible respectively for so-called SARS, MERS and COVID-19 diseases. (Painter et al., 2021); (Sheahan et al., 2020).
  • Lopinavir is a viral protease inhibitor, used as an antiviral against the human immunodeficiency virus (HIV). It is marketed in association with Ritonavir by Abbott laboratories, mainly under the name Kaletra.
  • Lopinavir works by inhibiting the production of functional proteins and enzymes by new virions, which blocks the spread of the virus.
  • Lopinavir is rapidly broken down in the body by the cytochrome P450 system. For this reason, it is only given in a fixed combination with Ritonavir.
  • This second drug which is also a protease inhibitor, has the function of inhibiting cytochrome P450 monooxygenases, and therefore of slowing down the degradation of Lopinavir by these enzymes. This makes it possible to significantly reduce the dose required, and therefore the number of tablets to be absorbed by the patient.
  • Camostat mesilate Camostat mesilate or Camostat mesilate (FOY-305) is a synthetic low molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. This compound is used in therapy to treat chronic inflammation of the pancreas. In addition, this compound attenuates the function of the epithelial sodium ducts of the respiratory tract, and improves mucociliary clearance.
  • Camostat mesilate tablets are approved in Japan and marketed under the brand name FOI PAN®. They are used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.
  • Patent EP 2 435 064 proposes targeting the serine proteases HAT and TMPRSS2 for the treatment of viral infections, in particular by influenza viruses.
  • Chloroquine initially known for its antimalarial activity, has an antiviral action on SARS-CoV according to data obtained in vitro (Vincent et al., 2005).
  • Chloroquine phosphate in the treatment of patients, at a rate of 500 mg twice a day for 10 days for patients diagnosed as mild, moderate and severe cases of disease, and without contraindication to Chloroquine.
  • New antiviral compounds are actively sought for the treatment and prevention against this emerging SARS-CoV-2 virus.
  • Diltiazem which is an active compound which acts on the host cell of the virus rather than directly on the virus, thus making it possible to have a broad spectrum of action and power. treat different viral infections.
  • International application WO 87/07508 describes the use of Diltiazem for the treatment of viral infections linked to cytomegalovirus or to herpes.
  • Berberine is a known active compound which may exhibit antiviral activity.
  • Berberine is an isoquinoline alkaloid produced by certain plants, in particular by the Berberi species, which is widely used in the Asian pharmacopoeia.
  • Berberine acts on various cellular pathways, and has antibacterial, antifungal, antiviral, anti-inflammatory and metabolic properties, improving hyperglycemia, type 2 diabetes, as well as hyperlipidemia. . (Mohan et al., 2017)
  • Berberine is particularly active in the fight against pulmonary arterial hypertension (PAH), a diffuse disease of pulmonary microvascular remodeling accompanied by a malignant proliferation of smooth muscle cells in the pulmonary artery, which causes a persistent rise in pulmonary arterial pressure. leading to right ventricular hypertrophy (HVD).
  • PAH pulmonary arterial hypertension
  • HVD right ventricular hypertrophy
  • Berberine also has excellent anti-inflammatory properties, reducing joint swelling, tissue infiltration and destruction by inflammatory cells.
  • Berberine regulates the polarization of macrophages, decreases the phagocytic function of macrophages, reduces the levels of M1 cytokines and increases the levels of M2 cytokines (IL-10 and transforming growth factor-b ⁇ or TGF-b1).
  • Berberine has a broad antibacterial spectrum, especially against infection with methicillin-resistant Staphylococcus aureus (MRSA). When applied in vitro and in combination with methoxyhydnocarpine, Berberine inhibits the growth of Staphylococcus aureus.
  • MRSA methicillin-resistant Staphylococcus aureus
  • Berberine exhibits antiviral activity on various viruses, including:
  • HCMV cytomegalovirus
  • HCV hepatitis C virus
  • ZIKV Zika virus
  • combination therapies based on the association of at least two antiviral compounds appear to be particularly effective for the treatment and / or prevention of infection by the SARS-CoV-2 coronavirus.
  • the present invention relates to a compound selected from Diltiazem, Berberine and their combination, for its therapeutic use in the treatment of viral infection with the SARS-CoV-2 virus (known as COVID-19 disease).
  • the present invention relates to Diltiazem for its therapeutic use in the prevention and / or treatment of viral infection with the SARS-CoV-2 virus, known as the COVID-19 disease.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, at least one compound chosen from Diltiazem and Berberine, for its therapeutic use in the treatment of viral infection by the SARS-CoV virus. -2 (known as COVID-19 disease).
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical vehicle, for its therapeutic use in the prevention and / or treatment of viral infection by the SARS-CoV-2 virus.
  • the present invention also relates to a composition for its use as described above, comprising at least one other active agent chosen from:
  • the preferred compounds are Remdesivir, Galidesivir, Molnupiravir, and combinations thereof.
  • the preferred compound is Lopinavir, and more preferably Lopinavir combined with Ritonavir.
  • the preferred compound is Camostat mesilate.
  • the present invention also relates to a combination product comprising at least one compound chosen from Diltiazem and Berberine, and at least one other active agent chosen from:
  • any mixture of the aforementioned compounds for its simultaneous, separate or sequential use in the prevention and / or treatment of a viral infection by the SARS-CoV-2 virus.
  • the present invention also relates to a combination product comprising Diltiazem and at least one other active agent chosen from:
  • any mixture of the aforementioned compounds for its simultaneous, separate or sequential use in the prevention and / or treatment of a viral infection with the SARS-CoV-2 virus.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, a combination of Diltiazem with Remdesivir; or a combination of Diltiazem with Molnupiravir.
  • FIG. 1 represents the antiviral effects of Berberine and Remdesivir as monotherapy on cultured Vero E6 cells infected with the SARS-CoV-2 virus.
  • Figure 1A chronogram of the experiment.
  • Figure 1 B Dose-effect curves of the molecules Berberine and Remdesivir in monotherapy and determination of the IC50 associated with 48 and 72 hours post-infection (hpi).
  • Remdesivir and Berberine exhibit an antiviral effect at 48 hpi, with an IC50 determined at 0.98 and 17.47 mM, respectively. This antiviral effect is even more pronounced at 72 hpi with IC50s of less than 0.72 and 5.60 mM for Remdesivir and Berberine, respectively.
  • FIG. 2 represents the antiviral effects of the Diltiazem / Remdesivir, Berberine / Remdesivir combinations on cultured Vero E6 cells infected with the SARS-CoV-2 virus.
  • Figure 2B Dose-effect curves of the Diltiazem / Remdesivir and Berberine / Remdesivir combinations, and determination of the IC50 associated with 48 and / or 72 hours post infection (hpi).
  • the combination of a treatment with Diltiazem in the presence of a fixed concentration of Remdesivir makes it possible to have antiviral efficacy with an IC50 of 0.55 mM, at 48hpi.
  • the combination of a treatment with Remdesivir in the presence of a fixed concentration of berberine (12.5 pM) makes it possible to have antiviral efficacy with an IC50 of 0.65 pM, at 48 hpi.
  • the combination of treatment with Remdesivir in the presence of a fixed concentration of Diltiazem (11 .5 mM) makes it possible to obtain antiviral efficacy with an IC50 of 0.35 pM.
  • Figure 3 illustrates some of the results presented in Figures 1B and 2B visually.
  • FIG. 3A chronogram of the experiment.
  • FIG. 3B Observation by light microscopy of the antiviral effect of Remdesivir and Diltiazem in monotherapy and in combination on a layer of Vero E6 cells in culture, and infected with SARS-CoV-2. Under the same experimental conditions as before (Fig. 2), the combination of Remdesivir (0.625 pM) and Diltiazem (11.5 pM) makes it possible to very visibly reduce the cytopathic effects of the infection (rounded cells and detached from the mat) in comparison untreated control, and monotherapy treatments.
  • FIG. 5 Chronogram of the experiment of example 4.
  • the A549-ACE2 cells are seeded and then infected with a viral strain of SARS-CoV-2, before being treated 1 h post-infection with Diltiazem or Remdesivir. .
  • FIG. 7 (A). Measurement of the IC50 of Diltiazem on A549-ACE2 cells infected with a viral strain of SARS-CoV-2. The viral titer is expressed as a percentage of the viral titer measured in the supernatant, relative to the viral titer measured in the wells of the untreated cells, as a function of the concentration of Diltiazem used. (B). Measurement of CC50 of Diltiazem on A549-ACE2 cells after 72 hours of treatment. The viability of the cells is expressed as a percentage of viability measured for the untreated cells. The results are presented according to the concentration of Diltiazem used. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention relates to Diltiazem for its therapeutic use in the prevention and / or treatment of viral infection with the SARS-CoV-2 virus, known as the COVID-19 disease.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, at least one compound chosen from Diltiazem and Berberine, for its therapeutic use in the treatment of viral infection by the SARS-CoV-2 virus (COVID -19).
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical vehicle, for its therapeutic use in the prevention and / or treatment of viral infection by the SARS-CoV-2 virus.
  • viral infection by the SARS-CoV-2 virus is meant the fact that an organism, human or animal, has cells that have been infected with the SARS-CoV-2 coronavirus, also referred to by the name COVID-19 .
  • SARS-CoV-2 virus designates on the one hand the coronavirus identified for the first time in Wuhan in China, and sequenced in early 2020 by a team from Fudan University in Shanghai ( Zhou et al., 2020); and on the other hand, includes all variants related to this first identified viral strain, which appeared subsequently, and in particular the following SARS-CoV-2 variant strains: i. the “Wuhan-like” strain used by the inventors, described in the examples; ii.
  • a viral infection is usually diagnosed by a healthcare professional, based on observing the symptoms of the infected patient. Additional laboratory tests may be necessary to confirm the diagnosis: blood and / or sputum and / or bronchoalveolar fluid tests.
  • the infection can in particular be established by carrying out a detection by molecular biology and / or a viral titration from respiratory samples, or by assaying the specific antibodies of SARS-CoV-2 circulating in the blood.
  • the detection in infected individuals of this specific virus is carried out by conventional diagnostic methods, in particular molecular biology (PCR) which make it possible to establish that it is indeed this SARS-CoV-2 virus, well known to the person skilled in the art.
  • PCR molecular biology
  • treatment refers to combating infection with the SARS-CoV-2 coronavirus in a human or animal body. Thanks to the administration of at least one composition according to the invention, the level of viral infection (infectious titer) in the organism will decrease, and preferably the virus will disappear completely from the organism within a period of less than that expected for a cure without treatment.
  • treatment also refers to alleviating the symptoms associated with the viral infection (respiratory syndrome, kidney failure, fever, etc.).
  • compositions according to the invention are also intended for use in the prevention of infection with SARS-CoV-2.
  • the present invention relates to: a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical vehicle, for its therapeutic use in the treatment of viral infection with the SARS-CoV-2 virus; a pharmaceutical composition comprising Berberine, in a suitable pharmaceutical vehicle, for its therapeutic use in the treatment of viral infection with the SARS-CoV-2 virus; and a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical vehicle, for its use in the prevention of viral infection with the SARS-CoV-2 virus.
  • prevention refers to preventing, or at least reducing the probability of occurrence, of an infection in a human or animal body by SARS-CoV-2. Thanks to the administration of at least one composition according to the invention, the human or animal cells of said organism become less permissive to infection, and are thus more likely not to be infected with said coronavirus, or to develop diseases. less severe symptoms during infection with said coronavirus.
  • compositions according to the invention may be of pharmaceutical type, intended to be administered to a human being, or of veterinary type, intended to be administered to patients. non-human animals. With regard to animals, it is understood that the veterinary compositions for their use in the prevention and / or treatment of an infection by the SARS-CoV-2 coronavirus are intended to be administered to animals infected with this coronavirus.
  • suitable pharmaceutical vehicle denotes pharmaceutical vehicles or excipients, which are compounds having no specific action on the infection considered here. These vehicles or excipients are pharmaceutically acceptable, which means that they can be administered to an individual or an animal without generating significant deleterious effects.
  • At least one compound selected from Diltiazem and Berberine means that the pharmaceutical composition comprises either Diltiazem or Berberine, or a combination of the two.
  • the pharmaceutical composition for its use according to the invention comprises at least an effective amount of Diltiazem.
  • This pharmaceutical composition is intended for therapeutic and / or preventive use against infection by the SARS-CoV-2 virus.
  • the pharmaceutical composition for its use according to the invention comprises at least one effective amount of berberine.
  • the pharmaceutical composition for its use according to the invention comprises at least an effective amount of Diltiazem and an effective amount of Berberine.
  • an effective amount is meant within the meaning of the invention an amount of active compound sufficient to inhibit the proliferation and / or replication of the coronavirus, and / or the development of viral infection within the body. This inhibition can be quantified, for example by measuring the viral titer, as presented in the examples of the present application.
  • the pharmaceutical composition for its use as described above comprises a combination of Diltiazem and Berberine.
  • the term "combination" means a composition comprising at least two distinct active compounds, the two compounds having antiviral action.
  • This combination includes either the same amount by weight of each antiviral compound, i.e. a combination of 50% Diltiazem and 50% Berberine by weight, or unequal doses of each compound, such as 90% Diltiazem.
  • Diltiazem and 10% Berberine 80% Diltiazem and 20% Berberine, 70% Diltiazem and 30% Berberine, 60% Diltiazem and 40% of Berberine, 40% of Diltiazem and 60% of Berberine, 30% of Diltiazem and 70% of Berberine, 20% of Diltiazem and 80% of Berberine, or even 10% of Diltiazem and 90% of Berberine, the percentages being expressed by weight of the compound relative to the total weight of the combination.
  • Diltiazem and 10% Berberine 80% Diltiazem and 20% Berberine
  • 70% Diltiazem and 30% Berberine 80% Dilti
  • Diltiazem is a member of the benzothiazepine family, referenced under the CAS number 42399-41-7.
  • Diltiazem denotes the molecule in the form of one of its L-cis or D-cis enantiomers, or of a racemic mixture of the two, or alternatively a Diltiazem salt as by example Diltiazem hydrochloride, the structural chemical formula of which is shown below, in formula (I):
  • Diltiazem has been known for over 30 years and is approved by drug regulatory authorities in Europe and the United States. It can be given as Diltiazem hydrochloride. Cardizem®, Cartia®, Taztia® and Dilacor® are its most common trade names.
  • Diltiazem is available in various dosage forms, such as a cream for topical application, as tablets or capsules for oral administration, as a powder for preparation of a solution for injection or as pharmaceutical preparations for inhalation (WO 02 / 094238, US 4,605,552).
  • the classic dosage in humans is 180 to 360 mg / day, administered in capsules or tablets, for its therapeutic use as a calcium channel blocker.
  • the first identified physiological property of this compound is the inhibition of calcium channels, and therefore the inhibition of intracellular calcium fluxes.
  • Diltiazem slows down the entry of transmembrane calcium into the myocardial muscle fiber and the smooth muscle fiber of the vessels. This makes it possible to decrease the intracellular calcium concentration reaching the contractile proteins.
  • Diltiazem In humans, the administration of Diltiazem is indicated for its vasodilator action, with the aim of reducing the work of the heart. It is thus used in the management of cardiac and circulatory disorders such as angina pectoris, high blood pressure, myocardial ischemias and tachycardia. Diltiazem also works by reversing the effects of angiotensin II, both renally and peripherally. Topically, Diltiazem may be indicated for chronic anal fissures.
  • Patent EP 1 117408 describes the use of Diltiazem, as a calcium channel inhibitor compound, to treat pathologies linked to the degeneration of photoreceptors of the retina.
  • Berberine is a natural alkaloid found in a large number of plants, particularly in the Berber species. Its CAS number is 633 66 9
  • the molecule in all its forms is designated by “Berberine”. Its developed chemical structure is shown schematically below: This molecule is widely used in the Asian pharmacopoeia, for its antifungal, antibacterial and anti-inflammatory properties.
  • AMPK Addenosine Monophosphate activated Protein Kinase
  • This ubiquitous enzyme plays a role in cellular energy homeostasis.
  • the main effect of AMPK activation is to (i) stimulate hepatic fatty acid oxidation and ketogenesis, (ii) inhibit cholesterol synthesis, lipogenesis and triglyceride synthesis, (iii) stimulate oxidation of fatty acids in skeletal muscles and uptake of glucose by muscles; and (iv) modulate insulin secretion by beta cells in the pancreas.
  • the half-life of Berberine is also low, around 4 hours. This implies that the daily doses should ideally be divided into 3 doses. For an adult the daily dose is generally 500 mg to 1500 mg.
  • composition for its use according to the invention comprises at least one compound chosen from Diltiazem and Berberine, and that it can therefore also include other active compounds, in addition to the suitable pharmaceutical vehicle.
  • Diltiazem and Berberine or their mixture can be used in therapy alone, or in combination with at least one other active agent.
  • Diltiazem and / or Berberine may be compounds which make it possible to improve the antiviral activity of Diltiazem and / or Berberine, or conversely, Diltiazem and Berberine may act as potentiating agents for these other active compounds.
  • the present invention relates to Diltiazem or Berberine or their combination, for their use in the potentiation of the antiviral effects of other therapeutic compounds used to treat and / or prevent viral infection by SARS-CoV-2, in particular those cited in the present application.
  • additional active compounds may be chosen from the pharmaceutical classes of agents mentioned in application WO 2015/157223, namely from antibacterial agents, antiparasitic agents, neurotransmission inhibitors, estrogen receptor inhibitors, inhibitors of DNA synthesis and replication, protein maturation inhibitors, kinase pathway inhibitors, cytoskeletal inhibitors, lipid metabolism inhibitors, anti-inflammatory agents, ion channel inhibitors, inhibitors of apoptosis and cathepsin inhibitors.
  • the pharmaceutical composition for its use as described above comprises at least one other active agent, in particular an antiviral agent.
  • antiviral agent or “antiviral compound” are understood to mean active agents which act on the viral load (also called infectious titer), by inhibiting either directly or indirectly replication and / or the dissemination of a virus and in particular, in the present case, of the SARS-CoV-2 coronavirus, within an infected organism.
  • the pharmaceutical composition for its use in the prevention and / or treatment of an infection by the SARS-CoV-2 coronavirus comprises, in addition to Diltiazem and / or Berberine, at least another antiviral agent.
  • this other antiviral agent will be used in the doses necessary to exhibit an antiviral action, this dose being designated as being “effective", this dosage being able to be easily determined by a person skilled in the art.
  • This combination comprises either the same amount by weight of each antiviral compound, i.e. a combination of 50% Diltiazem and / or Berberine and 50% of another antiviral agent by weight, or unequal doses of each compound, such as 90% Diltiazem and / or Berberine - 10% of the other antiviral agent, 80% - 20%, 70% - 30%, 60% - 40%, 40%
  • antiviral activity or “antiviral action” is meant either:
  • target cells are understood to mean cells infected with the coronavirus and / or likely to be infected in the near future, due to their immediate proximity to infected cells.
  • Antiviral agents are classified into different categories based on their mode of action. We can cite in particular:
  • nucleotide or ribonucleoside analogues which interfere with or stop the synthesis of DNA or RNA
  • RNA viruses nucleoside analogs, inhibitors of viral protease (s), helicase inhibitors, and inhibitors of cellular entry of the virus into target cells such as transmembrane serine protease inhibitors.
  • nucleoside analogue refers to a compound used to prevent viral replication in infected cells, such as, for example, aciciovir. These compounds have structures similar enough to nucleosides to be integrated into replicating viral DNA strands, but they act as end-chain agents and stop the action of viral DNA polymerase.
  • Such a compound will be chosen from a nucleoside analog of guanosine (for example Ribavirin), adenosine (for example Remdesivir or Galidesivir), cytidine (Molnupiravir) or thymidine, or their deoxy versions. -.
  • Ribavirin for example Ribavirin
  • adenosine for example Remdesivir or Galidesivir
  • cytidine Molnupiravir
  • thymidine or their deoxy versions.
  • a “viral protease inhibitor (s)” denotes an antiviral compound acting by inhibiting the action of at least one viral protease, a protein which allows the cleavage and assembly of viral proteins. , a process essential for obtaining new infectious virions. The virions obtained are then incapable of infecting new cells.
  • This therapeutic strategy is used in particular to treat viral infections by HIV (Human Immunodeficiency Virus).
  • a “transmembrane serine protease inhibitor” denotes an antiviral compound acting by inhibiting the entry of the virus into the cell, in particular by its action at the level of the transmembrane serine protease 2 designated by the abbreviation TMPRSS2.
  • composition for its use as described above comprises at least one other active agent chosen from:
  • the combination comprises Diltiazem and at least one nucleoside analogue.
  • the combination comprises Diltiazem and at least one inhibitor of viral protease (s).
  • the combination comprises Diltiazem and at least one transmembrane protein serine inhibitor, in particular that of type 2.
  • the combination comprises Diltiazem and Chloroquine.
  • the combination comprises Diltiazem and a mixture of at least two compounds chosen from:
  • the combination comprises Berberine and at least one nucleoside analogue.
  • the combination comprises berberine and at least one inhibitor of viral protease (s).
  • the combination comprises berberine and at least one transmembrane protein serine inhibitor, in particular that of type 2.
  • the combination comprises Berberine and Chloroquine.
  • the combination comprises Berberine and a mixture of at least two compounds chosen from:
  • the at least one nucleoside analog may in particular be chosen from the group consisting of: Remdesivir, Galidesivir, Molnupiravir and their combinations.
  • the at least one viral protease inhibitor (s) may in particular be Lopinavir, and preferably Lopinavir combined with Rinotavir.
  • the at least one transmembrane protein serine inhibitor in particular that of type 2, may in particular be Camostat mesilate.
  • the pharmaceutical composition for its use according to the invention comprises or consists of:
  • the pharmaceutical composition for its use according to the invention comprises or consists of:
  • the pharmaceutical composition for its use according to the invention comprises or consists of:
  • the composition for its therapeutic use as described above further comprises at least one antibiotic.
  • Such an antibiotic will be particularly useful in preventing bacterial superinfection with the current viral infection.
  • the antibiotic is chosen from antibiotics well known to those skilled in the art, in particular those used in viral infections to prevent bacterial superinfection, and in particular those of the macrolide family.
  • compositions according to the present invention are suitable for nasal, oral, sublingual, inhalation, subcutaneous, intramuscular, intravenous, transdermal, ocular or rectal administration.
  • the composition for its use as described above is characterized in that it is in a galenic form suitable for nasal administration, in particular intranasal, in particular by inhalation.
  • the intranasal route is a route of administration characterized in that the pharmaceutical composition is introduced directly into the nasal cavity of the patient, by various methods, for example: drops, spray, or inhaler.
  • drops, spray, or inhaler for example: drops, spray, or inhaler.
  • a specific device such as an intranasal mucosal spray device, is recommended.
  • the intranasal route offers the possibility of rapid, painless and non-invasive drug administration with an effectiveness often comparable to that of the intravenous route. It is particularly suitable in pediatrics or for the elderly, or in emergency medicine situations.
  • the pharmaceutical composition for its use as described above is administered intranasally.
  • the pharmaceutical composition for its use as described above is administered by inhalation.
  • Inhalation refers to absorption through the respiratory tract. It is in particular a method of absorbing compounds for therapeutic purposes, certain substances in the form of gas, micro-droplets or suspended powder.
  • compositions by inhalation that is to say by the nasal and / or oral passages, is well known to those skilled in the art.
  • compositions are in the form of powders
  • compositions are in the form of aerosols (suspensions) or in the form of solutions, for example aqueous solutions, placed under pressure.
  • a nebulizer or sprayer will then be recommended to administer the pharmaceutical or veterinary composition.
  • the dosage form considered here is therefore chosen from: a powder, an aqueous suspension of droplets or a solution under pressure.
  • the present invention also relates to a combination product comprising at least one compound chosen from Diltiazem and Berberine, and at least one other active agent chosen from:
  • any mixture of the aforementioned compounds for simultaneous, separate or sequential use in the prevention and / or treatment of viral infection with the SARS-CoV-2 virus (COVID-19).
  • This combination product will in particular be composed of:
  • this combination product will in particular be composed of:
  • this combination product will in particular be composed of:
  • one of these combination products as described above is used simultaneously, separately or sequentially, for the prevention of a viral infection by the SARS-CoV-2 virus. (COVID-19).
  • one of these combination products as described above is used simultaneously, separately or sequentially, for the treatment of a viral infection by the SARS-CoV virus. 2 (COVID-19).
  • This combination product may comprise other active compounds, and in particular at least one antibiotic.
  • the present invention also relates to a method for treating a patient infected with a SARS-CoV-2 virus (suffering from the disease known as COVID-19) comprising the administration to said patient of a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, the least one compound selected from Diltiazem and Berberine.
  • the present invention also relates to a method for preventing the appearance of a viral infection by a SARS-CoV-2 virus (called COVID-19 disease), in an individual likely to be infected with said virus, comprising the administration to said individual of a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, Diltiazem.
  • COVID-19 disease a SARS-CoV-2 virus
  • the present invention also relates to a method for treating a patient infected with a SARS-CoV-2 virus (suffering from the disease known as COVID-19), comprising the administration to said patient of a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, Diltiazem.
  • this method may also include the administration to said patient of another active compound, in particular chosen from the following compounds:
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, a combination of Diltiazem and / or Berberine, with Remdesivir.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, a combination of Diltiazem with Remdesivir.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, in a suitable pharmaceutical vehicle, a combination of Diltiazem with Molnupiravir.
  • said pharmaceutical composition comprises, in a suitable pharmaceutical vehicle, a combination of Diltiazem, Berberine, and Remdesivir.
  • the present invention also relates to pharmaceutical compositions comprising, in a suitable pharmaceutical vehicle, the following combinations:
  • Examples 1 to 3 demonstrate on the one hand the effectiveness of treatment with Diltiazem or Berberine as monotherapy, and on the other hand the advantage of using these molecules in combination with Remdesivir for the treatment of infections due to SARS-CoV-2.
  • the viral load was quantified in RT-qPCR and / or in TCID50 / ml in samples of infection supernatants from Vero E6 cells but also in apical washes and cell lysates of reconstituted human epithelium (HAE MucilAir, Epithelix), treated with Diltiazem, Berberine, or Remdesivir as monotherapy or in combinations of two of these molecules (Diltiazem + Remdesivir, or Berberine + Remdesivir).
  • the viral production relative to each of the concentrations of molecules was determined and is represented in relation to the viral production from infected cells or HAE in the same conditions but not treated.
  • Median inhibitory concentrations (IC50) were determined for each treatment condition.
  • the virus used was isolated from a sample of a patient infected with SARS-CoV-2.
  • the strain of SARS-CoV-2 used in this study was isolated from a 47-year-old female patient recruited from a French clinical cohort evaluating patients with COVID-19 (NCT04262921). This study was carried out in accordance with the Declaration of Helsinki and received the approval of the local ethics committee.
  • the viral strain was sequenced with Illumina MiSeq and deposited in the GISAID EpiCoVTM database under the reference BetaCoV / France / IDF0571 / 2020 (EPI identification number _ISL_411218). For reference see (Pizzorno et al., 2020).
  • Isolation of the virus was performed by inoculation of Vero E6 cells (ATCC CRL-1586) and monitoring the appearance of cytopathic effects. After the appearance of the first virus-induced effects, the infection supernatant was harvested and the viral RNAs were extracted therefrom using the QIAmp Viral RNA kit (QIAGEN). The extracted RNAs were then subjected to Illumina MiSeq sequencing (Zymo-Seq RiboFree), with 500x coverage, and the sequences were assembled using the hisat2 and consensus alignment programs.
  • the sequence was then deposited on the GISAID EpiCoV platform (Accession ID EPI _ ISL _ 411218) under the name BetaCoV / France / IDF0571 / 2020.
  • This viral strain is phylogenetically very close to the strains of SARS-CoV-2 which circulated at the start of the epidemic in the Wuhan region in China in January / February 2020. This strain is therefore representative of the strains of SARS-CoV -2 at the origin of infectious diseases known as "COVID-19" currently observed today in the world.
  • Vero E6 cells (ATCC CRL-1586) were cultured in DMEM medium 4.5 g / l of Glucose, supplemented with L-Glutamine and Penicillin / streptomycin and 10% inactivated fetal calf serum, at 37 ° C 5% CO 2.
  • the cells were rinsed twice with serum-free medium and were covered with a minimum volume containing a dilution of virus, this dilution being determined from the infectious titer (see chapter determination of the infectious titer), in order to obtain an adequate multiplicity of infection (MOI).
  • MOI multiplicity of infection
  • HAE MucilAir a model of reconstituted human epithelium (HAE MucilAir, Epithelix), obtained from human primary cells obtained by nasal biopsies, cultured at the air-liquid interface with a specific culture medium in Costar Transwell inserts (Corning, NY, USA.
  • HAE MucilAir a model of reconstituted human epithelium obtained from human primary cells obtained by nasal biopsies, cultured at the air-liquid interface with a specific culture medium in Costar Transwell inserts (Corning, NY, USA.
  • OptiMEM medium Gibco, ThermoFisher Scientific
  • MOI multiplicity of infection
  • the determination of the infectious titer was carried out by a limit dilution technique, on these Vero E6 cells in a 96-well plate. A volume of 50 ml of serial dilutions is deposited in wells in quadruplicates. The cells are then incubated at 37 ° C. 5% CO 2 and the presence of cytopathic effects is then monitored after 3 days of infection.
  • the 50% tissue culture infectious dose (TCID50 / ml) that is, the viral titre required to cause infection in 50% of the inoculated cells, was calculated using the technique of Reed and Muench.
  • a quantitative “one-step” PCR was carried out using the StepOnePlus Real Time PCR System kit (Applied Biosystems), with the EXPRESS One-Step Superscript qRT-PCR reagent (Invitrogen), in a reaction volume of 20 mI containing 10 mI of supermix Express qPCR (2x), 1 mI of each primer (10 mM), 3.1 mI of water, 0.4 mI of Rox dye (25 mM) and 2 mI of viral RNA.
  • FAM and TAMRA denote fluorescent markers.
  • Example 2 Comparison of IC50s of Diltiazem, Berberine, Remdesivir, and Diltiazem + Remdesivir and Berberine + Remdesivir Combinations on SARS-CoV-2 Virus in Vero E6 Cell Model.
  • Vero E6 cells infected with SARS-CoV-2 (MOI 0, 1) were treated one hour after infection with increasing concentrations:
  • a dose of one of the molecules was set and associated with increasing concentrations of the other molecule (same concentration ranges as those used in monotherapy, respectively) and vice versa.
  • the viral infectious titers measured in the culture supernatants of the infected cells reflect the level of viral replication under the various treatment conditions.
  • Table 2 summarizes the IC50 data for different monotherapy and / or combination treatments obtained in Vero E6 cells at different times of SARS-CoV-2 infection.
  • Remdesivir In parallel, Diltiazem combined with a fixed concentration of Remdesivir makes it possible to obtain an IC50 of 0.55 pM, while its IC50 is greater than 45 pM at 48hpi. In addition, Remdesivir combined with a fixed concentration of Berberine (12.5 pM) achieves a reduction of approximately 33% of its IC50 (0.65 versus 0.98 pM) at 48hpi.
  • Example 3 Comparison of the Antiviral Activities of Diltiazem, Berberine, Remdesivir, and Diltiazem + Remdesivir, Berberine + Remdesivir Combinations on SARS-CoV-2 Virus in a Reconstituted Human Respiratory Epithelium Infection Model.
  • Reconstituted human respiratory epithelia of nasal origin and cultured at an air / liquid interface (MucilAir® HAE, Epithelix) were infected with SARS-CoV-2 (MOI 0.1).
  • the basal medium was treated once a day with the following molecules, as a single treatment or in combination: - Diltiazem (45 or 90 mM),
  • Figure 4 shows the chronogram of the experiments. At different times, the epithelia were harvested and lysed. Total RNA was extracted and viral genomes were quantified by RT-PCR by normalizing data using quantification of cellular gene product (GAPDH).
  • GPDH cellular gene product
  • Table 3 shows the effects of Diltiazem, Berberine and Remdesivir monotherapy treatments and Diltiazem + Remdesivir, Berberine + Remdesivir combined treatments on SARS-CoV-2 virus replication in a human respiratory epithelium model (MucilAir® HAE, Epithelix) of nasal origin.
  • Table 3 summarizes the data for antiviral activities of Diltiazem, Berberine, Remdesivir, and Diltiazem / Remdesivir, Berberine / Remdesivir combinations on SARS-CoV-2 virus in a reconstituted human respiratory epithelium infection model. nasal or bronchial origin. Remdesivir, as a single treatment, exhibits significant efficacy at 48hpi in epithelium of nasal origin (more than 7.75 Iog10 of reduction in viral replication).
  • Remdesivir with Diltiazem or with Berberine (under the same concentration conditions as in monotherapy) significantly increases the antiviral effect (8.6 and 8.29 Iog10 of reduction in viral replication for combination with Diltiazem and Berberine, respectively).
  • the Remdesivir / Diltiazem combinations exhibit efficacy in epithelium of nasal origin, but without significant difference with simple treatment with Remdesivir. This could be explained by the limited antiviral efficacy of Diltiazem under these experimental conditions (0.16 / 0.15 Iog10 reduction in nasal epithelium.
  • Cells of the A549 cell line are human alveolar basal epithelial cells derived from adenocarcinoma. This cell line is used as a model for the study of lung cancer, but also as target cells for infectious viruses targeting the respiratory tract. These cells were subsequently modified to express the AC E2 receptor, through which the SARS-CoV-2 virus enters host cells.
  • This A549-ACE2 cell line was obtained from Creative Biogene (USA).
  • these A549-ACE2 cells Unlike Vero cells, these A549-ACE2 cells have a complete and functioning interferon signaling pathway. They are therefore more suitable for studying the effects of Diltiazem, which acts on these signaling pathways.
  • the experimental protocol is as follows:
  • SARS-CoV-2 (MOI 10 1 and 10 2 )
  • the incubation media used are as follows:
  • Inoculation medium DMEM 1 g / L glucose (GIc), 200mM L-Glutamine (L-Glu), 104 units Penicillin / Streptomycin (P / S), 10% Fetal Calf Serum (FCS)
  • Treatment medium DMEM 1 g / L GIc, 200mM L-Glu, 104 U P / S, 2% FCS
  • FIG. 5 shows the experimental protocol: a single treatment is carried out at 1 h pi, then the supernatant is taken at 24, 48, 72 and 96 hpi.
  • Remdesivir and Diltiazem make it possible to obtain, with a single treatment, the same level of inhibition of the viral titer (measured by RT-PCR) over time, regardless of the rate of multiplicity of infection.
  • the experimental protocol is as follows:
  • the supernatants are taken 72 hours after infection for viral quantification by RT-PCR.
  • the IC50 is the median inhibitory concentration, that is, the amount of Diltiazem required to achieve 50% inhibition of viral replication of the strain SARS-CoV-2 tested.
  • CC50 Cytotoxic concentration 50%
  • Viability was determined by an MTS test performed 72 hours after the start of treatment.
  • the MTS test is a colorimetric method: the method is based on the reduction of the tetrazolium compound MTS by viable cells to generate a colored formazan product, allowing the counting of viable (stained) cells and dead cells.
  • Mohan MC Abhimannue AP
  • B PK Identification and Characterization of Berberine in Tinospora cordifolia by Liquid Chromatography Quadrupole Time of Flight Mass Spectrometry (LC MS / MS Q-tof) and Evaluation of its anti Inflammatory Potential. Pharmacognosy Journal. 2017; 9 (3): 350-355

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21717141.2A 2020-03-10 2021-03-10 Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2 Withdrawn EP4117669A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2002351A FR3108033B1 (fr) 2020-03-10 2020-03-10 COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2
PCT/FR2021/050406 WO2021181044A1 (fr) 2020-03-10 2021-03-10 Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2

Publications (1)

Publication Number Publication Date
EP4117669A1 true EP4117669A1 (fr) 2023-01-18

Family

ID=71094490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21717141.2A Withdrawn EP4117669A1 (fr) 2020-03-10 2021-03-10 Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2

Country Status (8)

Country Link
US (1) US20230210866A1 (zh)
EP (1) EP4117669A1 (zh)
JP (1) JP2023517639A (zh)
CN (1) CN116018143A (zh)
CA (1) CA3170621A1 (zh)
FR (1) FR3108033B1 (zh)
IL (1) IL296342A (zh)
WO (1) WO2021181044A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114224896A (zh) * 2021-12-30 2022-03-25 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 病毒感染症的预防和早期治疗用组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326089A1 (de) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
US4849412A (en) 1986-06-05 1989-07-18 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
WO2002094238A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
DE102009022794A1 (de) 2009-05-27 2010-12-02 Philipps-Universität Marburg Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel
CA2687013C (en) 2009-12-03 2018-09-04 Kenneth W. Adams Method and composition for treatment and prevention of broad spectrum virus ailments
US20150140121A1 (en) 2012-06-08 2015-05-21 Lankenau Institute For Medical Research Compositions and Methods for Tight Junction Modulation
US10434116B2 (en) 2014-04-07 2019-10-08 University Of Maryland, Baltimore Methods of treating coronavirus infection
FR3033701B1 (fr) 2015-03-19 2021-01-15 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe
FR3057773B1 (fr) 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
FR3081325B1 (fr) 2018-05-23 2020-10-09 Univ Claude Bernard Lyon Diltiazem pour son utilisation dans le traitement des infections microbiennes

Also Published As

Publication number Publication date
WO2021181044A1 (fr) 2021-09-16
CN116018143A (zh) 2023-04-25
US20230210866A1 (en) 2023-07-06
CA3170621A1 (fr) 2021-09-16
FR3108033A1 (fr) 2021-09-17
IL296342A (en) 2022-11-01
JP2023517639A (ja) 2023-04-26
FR3108033B1 (fr) 2023-04-21

Similar Documents

Publication Publication Date Title
Liang et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
EP3528835B1 (fr) Compositions antivirales pour le traitement des infections liees aux coronavirus
EP3270968B1 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
WO2013131496A1 (zh) 治疗病毒疾病的成分和方法
WO2021181044A1 (fr) Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2
EP3796916A1 (fr) Diltiazem pour son utilisation dans le traitement des infections microbiennes
WO2022228651A1 (en) Pyruvate esters for the treatment of viral diseases
LU85854A1 (fr) Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1,2,4-triazole-3-carboxamide
Koelsch et al. Anti-rhinovirus-specific activity of the alpha-sympathomimetic oxymetazoline
Goc et al. Simultaneous inhibition of SARS-CoV-2 infectivity by a specific combination of plant-derived compounds
CN115666550A (zh) 用于预防和/或治疗冠状病毒的半胱氨酸蛋白酶抑制剂
FR3049861A1 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
TWI853344B (zh) 草藥組成物、其製備方法及其用途
TW201006481A (en) Pharmaceutical compositions for treating rotavirus and/or respiratory syncytial virus infection and manufacturing method thereof
EP4201404A1 (en) Antiviral compounds for use in the treatment of coronavirus infection
CA3164270A1 (fr) Combinaison de diltiazem et des inhibiteurs de polymerase(s) virale(s)
Hewedy Broad Spectrum Antivirals to Combat COVID 19: the Reality and Challenges
JP2024507287A (ja) Ｒｎａウイルス感染の処置のためのｄｈｏｄｈ阻害性ｎｅｕｒｏｌａｅｎａ葉に基づく治療組成物
FR3109724A1 (fr) Dérivé de benzoporphyrine et son utilisation en tant qu'anti-viral
CN118434435A (zh) 用于治疗病毒感染的药物组合物
WO2021224836A1 (en) A synergistic formulation for management of respiratory pathogens including coronaviruses
WO2021255226A1 (en) Antiviral use of calixarenes
WO2016089904A1 (en) Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231113

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240116